HomeENGLISH MAGAZINECOVID-19 in kids: what data about admissions, seriousness and complications are there?

COVID-19 in kids: what data about admissions, seriousness and complications are there?

Children with SARS-CoV2 infection show a broad range of clinical presentations, from asymptomatic to a critical or fatal infection. In most cases, respiratory symptoms, fever, and in some cases, diarrhea, fever, and loss of smell, are typical. Some children develop severe inflammatory sequelae involving multiple organ systems, called the multisystem inflammatory syndrome in children (MIS-C). PIMS or MIS-C usually occurs 2 to 6 weeks after SARS-CoV-2 infection, and the most common symptom in all affected children is persistent fever, while other clinical features such as acute abdominal pain, muscle pain, diarrhea or vomiting, headache, and fatigue vary across affected children. Hyperemia and exanthema, a “strawberry tongue” and swollen hands and feet resembling Kawasaki´s disease have been seen in a high proportion of PIMS/MIS-C patients. Cardiovascular issues such as myocardial dysfunction, arterial hypotension, or systemic shock have also been regularly seen, while myocarditis, pericarditis, and valve and coronary artery involvement may also develop.

Lab analyses show intensive inflammation with elevated levels of serum C-reactive protein, ferritin, procalcitonin, troponin, and markers of coagulopathy and hematologic abnormalities. Most children affected by PIMS will need ICU care due to multiorgan failure and shock. Studies have discussed a possible involvement of pathogenetically relevant autoantibodies in MIS-C. Scientists recently discovered neutralizing autoantibodies against the IL-1-receptor antagonist (IL-1-Ra) and anti-inflammatory receptor antagonists progranulin (PGRN) in adult patients with severe COVID-19. While risk factors for hospitalization and poor outcomes are well documented in adults, less is known about the clinical factors associated with COVID disease severity in children. In an effort to aid mitigation strategies for children who are at high risk of developing severe COVID disease, a group of physicians at Monroe Carell Jr. Children’s Hospital at Vanderbilt studied data from 45 children’s hospitals around the country; overall 20.000 patients were included.

The study, published in the Journal of Hospital Medicine, determined the factors associated with severe disease and poor health outcomes among children presenting to the hospital with COVID. These included older age and chronic co-morbidities such as obesity, diabetes and neurologic conditions, among others. The retrospective cohort study noted that approximately 1 out of every 4 children admitted to the hospital with COVID developed severe disease and required ICU care during April and September, 2020. Since most reports on SARS-CoV2 infection in children are based on cohorts of hospitalized children, leading to the full spectrum of disease having escaped description. The current report focuses on social and demographic characteristics of the pediatric population, along with the clinical phenotypes, symptom duration, and outcomes in this population. The initial period of the pandemic did not seriously affect children partly due to their relative isolation from sources of infection via school closures.

However, the delta variant of SARS-CoV2 that is currently spreading has affected children more than that initial period. This is why a reasearch in the journal BMC Pediatrics describes the clinical phenotypes and outcomes in a thousand children who developed COVID-19. This led to the identification of risk factors for hospitalization. The study took place in a large pediatric hospital in the southeast of the USA. The researchers found that the first thousand pediatric patients with SARS-CoV2 infection were enrolled in hospital records between March 13 and September 28 in 2020. Almost two-thirds of these children had close contact with a known infected individual. About one in five had another medical condition. While 80% of tests were in the outpatient setting, the remaining were from the emergency department, with a small fraction being returned after admission. The median period from symptom onset to testing was two days. More than half the children presented with cough, while 43% had a headache.

A little more than one in three had a sore throat, with a similar proportion reporting fever. Younger children had fever and rash more often, but older children more often reported sore throat and muscle pains. In this group, 75% of children had one or more symptoms connected to the respiratory system, two-thirds had a general symptom, and just over a quarter had gut symptoms. Respiratory symptoms included cough, runny nose, sore throat, or difficulty in breathing. In two-thirds of the respiratory-symptom group, these were accompanied by one or more general symptoms such as headache, muscle pain, anosmia, fatigue, or a rash. A quarter had respiratory symptoms and one gut-related symptom such as nausea/vomiting, diarrhea and abdominal pain. About 4% of the patients required hospitalization, two-thirds of hospitalized children had another medical condition. Fewer than 1% (eight children) needed intensive care unit (ICU) admission, and two children needed mechanical ventilation. Only one child later developed MIS-C, and there was one death in the whole group, possibly due to the infection.

About 45% of children reported complete recovery at a median of two days from diagnosis. Older children were more likely to have continuing symptoms at this time. Most children (94%) recovered from their symptoms within a month. At 30 days, there were 28 patients with symptoms like tiredness, fatigue, and reduced smell sensation. There were no instances of long COVID-19 in this cohort. According to their analysis, the presence of another medical condition increased the risk of hospitalization almost eight times, while shortness of breath increased it seven times. The presence of vomiting increased the risk by five times. Black or Hispanic origin was associated with an increase by three times. The studies demonstrated that most children with SARS-CoV2 infection had favorable outcomes, did not require hospitalization, and often recovered within two days of diagnosis. The reason for this difference in the severity between adults and children is unknown. The increased expression of the host cofactor TMPRSS2 in lung cells with age may be one explanation.

Despite the lower susceptibility to infection and severe disease, it remains true that three million children have been infected in the USA so far. Hispanic children, and those with infected siblings, are at higher risk. Such considerations may drive mitigation strategies. The mildness of infection in this age group means that the extent to which children drive household transmission is not yet established. The impact of school closures on the viral spread from children to adults may thus not be as effective as envisaged. The risk factors for hospitalization differ between children and adults. In the latter, being male, older, and obese increases the risk of severe COVID-19. However, obesity and male sex were not found to be risk factors for hospitalization in children. Hispanic or Black ethnicity, vomiting, having another medical condition or presenting with dyspnea predicted a higher risk of severe disease.

Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.

Scientific references

Howard L et al. BMC Pediatrics 2021; 21(1):403.

Pfeider J et al. medRxiv 2021 Sept 8; 21263027.

Antoon JW et al. J Hosp Med 2021; 16(5):294-97.

Dott. Gianfrancesco Cormaci
- Laurea in Medicina e Chirurgia nel 1998 (MD Degree in 1998) - Specialista in Biochimica Clinica nel 2002 (Clinical Biochemistry residency in 2002) - Dottorato in Neurobiologia nel 2006 (Neurobiology PhD in 2006) - Ha soggiornato negli Stati Uniti, Baltimora (MD) come ricercatore alle dipendenze del National Institute on Drug Abuse (NIDA/NIH) e poi alla Johns Hopkins University, dal 2004 al 2008. - Dal 2009 si occupa di Medicina personalizzata. - Guardia medica presso strutture private dal 2010 - Detentore di due brevetti sulla preparazione di prodotti gluten-free a partire da regolare farina di frumento immunologicamente neutralizzata (owner of patents concerning the production of bakery gluten-free products, starting from regular wheat flour). - Responsabile del reparto Ricerca e Sviluppo per la società CoFood s.r.l. (leader of the R&D for the partnership CoFood s.r.l.) - Autore di un libro riguardante la salute e l'alimentazione, con approfondimenti su come questa condizioni tutti i sistemi corporei. - Autore di articoli su informazione medica e salute sui siti web salutesicilia.com, medicomunicare.it e in lingua inglese sul sito www.medicomunicare.com
- Advertisment -

ARTICOLI PIU' LETTI

CHIUDI
CHIUDI